Gilead buys YM for $510m


US pharma company Gilead is to buy YM BioSciences, a drug discovery firm based in Ontario, Canada, for $510 million (£310 million).

The lead drug candidate at YM is CYT387, a selective inhibitor of the Janus kinase (JAK) enzymes, which are thought to be involved in several of disorders, including myeloproliferative diseases, inflammatory disorders and certain types of cancer.

Gilead is planning a Phase III trial of CYT387 against myelofibrosis in the second half of 2013.

YM gained CYT387 when it bought Australian biotech Cytopia in 2009.


Related Content

Myelofibrosis drug approved in EU

28 August 2012 Business

news image

Jakavi (ruxolitinib) tablets are for the treatment of myelofibrosis, a rare disease affecting the bone marrow

Business roundup

22 December 2011 Business

news image

Industry news, January 2012

Most Read

No-frills coats set a trend for designer viruses

26 August 2014 Research

news image

An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...

Rigid molecular wires make electrons fly

29 August 2014 Research

news image

Organic wires conduct electrons 800 times faster than other molecular counterparts by hitching a ride on a vibrational wave

Most Commented

Rigid molecular wires make electrons fly

29 August 2014 Research

news image

Organic wires conduct electrons 800 times faster than other molecular counterparts by letting them hitch a ride on a vibratio...

Concerns over chemical treatment of reclaimed fracking fluid

29 August 2014 Research

news image

Current recycling procedure may do more harm than good